NEW YORK, June 4 /PRNewswire-FirstCall/ -- Medicsight PLC (AIM: MDST), a subsidiary of MGT Capital Investments, Inc. (Amex: MGT) (the "Company"), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, today announces the signing of an exclusive CAD clinical research agreement with leading US CT Colonography radiologists, Dr. Perry Pickhardt and Dr. David Kim, from the University of Wisconsin Medical School, Madison, WI.
Dr. Pickhardt, Associate Professor of Radiology and Dr. Kim along with The University of Wisconsin were the first group to establish a third-party reimbursed CT colonography colorectal cancer screening programme in 2004. Since then they have both played an instrumental role in building the clinical evidence base that has proven the comparable effectiveness of CTC for the detection of colorectal neoplasia within an asymptomatic population in relation to Optical Colonoscopy. A key milestone recently achieved, partly as a result of their research, was the release of the American Cancer Society 2008 Consensus Guidelines that focus on colon cancer prevention and for the first time have recommended CTC be provided every five years for adults aged 50 years and over.
Commenting on the collaboration, Dr. Perry Pickhardt said, "Dr. Kim and I are excited about the Medicsight CAD research collaboration. This work promises to further improve the clinical performance of CAD and help define its role within colon cancer screening programmes in the USA."
David Sumner, CEO of Medicsight, commented, "I am delighted that Perry Pickhardt and David Kim, global leaders in CTC and radiology, have entered into this exclusive research agreement with Medicsight. Their specialist advice and vast experience of CTC practice will greatly enhance the clinical validation of Medicsight's ColonCAD products set in the context of the world's largest healthcare market. As a company we underpin all our efforts with best of breed clinical research. This research partnership clearly demonstrates this fact to both our partners and their customers alike."
About MGT Capital Investments, Inc.
MGT Capital Investments, Inc is a technology holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.
Medicsight PLC (AIM: MDST) is a leading developer of computer-aided detection (CAD) software solutions. Medicsight's CAD solutions help clinicians utilizing Computed Tomography (CT) scans to identify, measure and analyze suspicious pathology within the colon and lungs. The Medicsight CAD products are validated against one of the world's largest databases of verified CT scan data collected from leading healthcare institutions from around the world. Medicsight products allow radiologists and physicians to review scans more quickly and accurately -- saving both time and lives
Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.
Additional information can be found at www.mgtci.com .
All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.
SOURCE MGT Capital Investments, Inc.
